Wave Life Sciences, Inc. (WVE)
NasdaqGM · USD · Healthcare · Biotechnology
$3.21 (+0.94%) as of
Key statistics
- Market cap
- 633.10M
- Forward P/E
- -2.75
- EPS (TTM)
- -1.0800
- Dividend yield
- 0.00%
- 52-week range
- 3.0400 – 21.7300
- Beta
- -1.43
- Revenue (TTM)
- 65.37M
- Profit margin
- 0.00%
- Analyst target
- $17.68
- Volume
- 3.22M
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cambridge, MA, United States
- Employees
- 317
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.